Langtry H D, McTavish D
Adis Drug Information Services, Auckland, New Zealand.
Drugs. 1990 Nov;40(5):748-61. doi: 10.2165/00003495-199040050-00008.
Terodiline has both anticholinergic and calcium antagonist properties and, as a result, effectively reduces abnormal bladder contractions caused by detrusor instability. When administered to adult patients with urge incontinence (generally as a 25mg twice-daily dose) terodiline reduces diurnal and nocturnal micturition frequency and incontinence episodes. In studies also assessing cystometric parameters, bladder volume at first urge and bladder capacity are increased. Children with diurnal enuresis respond similarly to a daily 25mg dose. Several studies have shown that terodiline 50 mg/day is preferred by patients when compared with emepronium 600 mg/day or flavoxate 600 mg/day, and tends to reduce voluntary micturition frequency and episodes of incontinence more effectively than these drugs. Terodiline is well tolerated in short and long term (up to 3.5 years) studies. Anticholinergic effects are most commonly reported; other adverse effects occur equally during terodiline and placebo treatment. Thus, terodiline is effective and well tolerated in patients with urge incontinence or neurogenic bladder dysfunction, and will claim an important place in the treatment of such patients in light of the limitations of alternative therapies.
特罗地林兼具抗胆碱能和钙拮抗剂特性，因此能有效减少逼尿肌不稳定引起的膀胱异常收缩。给患有急迫性尿失禁的成年患者用药时（一般每日两次，每次25毫克），特罗地林可减少日间和夜间排尿频率及尿失禁发作次数。在同时评估膀胱测压参数的研究中，首次出现尿意时的膀胱容量和膀胱总容量均会增加。患有日间遗尿症的儿童对每日25毫克的剂量反应相似。多项研究表明，与每日600毫克的依美溴铵或每日600毫克的黄酮哌酯相比，患者更倾向于选择每日50毫克的特罗地林，且该药在减少自主排尿频率和尿失禁发作次数方面比这些药物更有效。在短期和长期（长达3.5年）研究中，特罗地林耐受性良好。最常报告的是抗胆碱能效应；在特罗地林治疗和安慰剂治疗期间，其他不良反应的发生几率相同。因此，特罗地林对患有急迫性尿失禁或神经源性膀胱功能障碍的患者有效且耐受性良好，鉴于替代疗法存在局限性，它将在这类患者的治疗中占据重要地位。
